OVERVIEW

Advancements in Migraine Therapies: Opportunities for Pharmacists to Intervene is organized by Pharmacy Times Continuing Education (PTCE) and will be held from Apr 12, 2019 - Apr 12, 2020.

Release Date: April 12, 2019
Expiration Date: April 12, 2020

Target Audience:
Retail pharmacists

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs)

Activity Overview:
Only one-third of individuals who are eligible for migraine preventive regimens actually receive them, and over 75% of these individuals become noncompliant due to adverse effects and lack of efficacy. Recently, calcitonin gene-related peptide (CGRP) antagonists were approved for preventive treatment against migraines, and they have been proven to be more effective and safer than previous therapies. Pharmacists have an important role in educating patients on medication and proper administration along with encouraging patient compliance in order for the patient to receive optimal therapeutic effects.

Educational Objectives:
At the completion of this activity, the participant will be able to:
• Examine the clinical features associated with migraines
• Explain safety and efficacy of newly approved agents for migraines
• Identify opportunities for pharmacists to intervene to optimize migraine treatment and prevent adverse drug effects

Additional details will be posted as soon as information is available.